Riboflavin in neurological diseases: therapeutic advances, metabolic insights, and emerging genetic strategies
Frontiers in Neurology · 02.09.2025 · 16
DOI: 10.3389/fneur.2025.1663136 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Frontiers in Neurology, online erschienen am 02.09.2025. Verfasst von Zhiming Tao und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatric Neurology, Children's Medical Center, The First Hospital of Jilin University, Changchun, China. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 95 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Riboflavin (vitamin B2), a precursor of flavin mononucleotide (FMN) and flavin adenine dinucleotide (FAD), is essential for mitochondrial function, redox balance, and neuronal viability. Impairments in riboflavin transport and metabolism contribute to a growing spectrum of neurological diseases.
Objective
This review provides a comprehensive update on the therapeutic applications, metabolic mechanisms, and gene-based strategies involving riboflavin in neurological disorders.
Methods
We systematically analyzed clinical and experimental studies published between 2012 and 2025, focusing on riboflavin-responsive conditions and molecular mechanisms relevant to neurological pathology.
Results
Riboflavin supplementation—particularly in high doses—has demonstrated substantial efficacy in conditions such as riboflavin transporter deficiency (RTD), multiple acyl-CoA dehydrogenase deficiency (MADD), and migraine. Emerging data suggest potential benefit in Parkinson’s disease, Alzheimer’s disease, multiple sclerosis, and acute brain injury. Mechanistically, riboflavin supports mitochondrial bioenergetics, antioxidant systems, and epigenetic regulation. Recent advances in gene therapy and pharmacological chaperones targeting riboflavin-dependent pathways offer promising therapeutic directions.
Conclusion
Riboflavin is evolving from a conventional micronutrient into a multifaceted therapeutic agent in neurology. Integration of gene-based approaches, targeted delivery systems, and biomarker-guided interventions may establish riboflavin as a key component of precision medicine strategies for neurological disorders.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pediatric Neurology, Children's Medical Center, The First Hospital of Jilin University, Changchun, China.
- Jilin Provincial Key Laboratory of Pediatric Neurology, Changchun, China.
- Neuromedical Center, First Hospital of Jilin University, Changchun, China.
Zitieren
APA
Tao, Z., Huo, J., Hao, X., & Liang, J. (2025). Riboflavin in neurological diseases: therapeutic advances, metabolic insights, and emerging genetic strategies. Frontiers in Neurology, 16. https://doi.org/10.3389/fneur.2025.1663136
Vancouver
Tao Z, Huo J, Hao X, Liang J. Riboflavin in neurological diseases: therapeutic advances, metabolic insights, and emerging genetic strategies. Frontiers in Neurology. 2025;16. doi:10.3389/fneur.2025.1663136
BibTeX
@article{Tao2025,
author = {Tao, Zhiming and Huo, Jinglu and Hao, Xiaosheng and Liang, Jianmin},
title = {Riboflavin in neurological diseases: therapeutic advances, metabolic insights, and emerging genetic strategies},
journal = {Frontiers in Neurology},
year = {2025},
volume = {16},
doi = {10.3389/fneur.2025.1663136}
}
EUVIMED